Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2005-03-15
2005-03-15
Saidha, Tekchand (Department: 1652)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C435S196000, C435S252300, C435S320100, C435S091500, C435S023000, C435S091500, C435S412000
Reexamination Certificate
active
06866844
ABSTRACT:
The present invention provides a highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase and biologically active mutants, fragments and analogs thereof as well as pharmaceutical formulations comprising highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase. The invention also provides methods for treating diseases caused all or in part by deficiencies in human N-acetylgalactosamine-4-sulfatase including MPS VI and methods for producing and purifying the recombinant precursor enzyme to a highly purified form.
REFERENCES:
patent: WO 0183722 (2001-11-01), None
Anson, et al., “Correction of Human Mucopolysaccharidosis Type-VI Fibroblasts with Recombinant N-Acetylagalactosamine-4-Sulphatase,”Biochem. J. 284:789-794 (1992).
Bielicki, et al., “Advantages of Using Same Species Enzyme for Replacement Therapy in a Feline Model of Mucopolysaccharidosis Type VI,”Journal of Biological Chemistry, 274(51):36335-36343 (1999).
Brooks, et al., “Enzyme Replacement Therapy In Mucopolysaccharidosis VI: Evidence for Immune Response S and Alteed Efficacy of Treatment in Animal Models,”Biochim. Biophys. Acta, 1361:203-216 (1997).
Byers, et al., “Effect of Enzyme Replacement Therapy on Bone Formation in a Feline Model of Mucopolysaccharidosis Type VI,”Bone, 21(5):425-431 (1997).
Crawley, et al., “Enzyme Replacement Therapy from Birth in a Feline Model of Mucopolysaccharidosis Type VI,”J. Clin. Invest., 99(4):651-662 (1997).
Crawley, et al., “Enzyme Replacement Therapy from Birth in a Feline Model of Maroteaux-Lamy Syndrome,”J. Clin. Invest., 97(8):1864-1873 (1996).
Haskins, et al., “Spinal Cord Compression and Hindlimb Paresis in Cats with Mucopolysaccharidosis VI,”J. Am. Vet. Med. Assoc., 182:983-985 (1983).
Haskins, et al., “The Pathology of the Feline Model of Mucopolysaccharidosis VI.,”Am. J. Pathol., 101:657-674 (1980), Abstract.
Hoogerbrugge, et al., “Allogenic Bone Marrow Transplantation for Lysosomal Storage Diseases,”Lancet, 345:1398-1402 (1995).
Inherited Disease, eds. Scriver t al., New York:McGraw-Hill, 1989, pp. 1565-1587.
Jezyk, et al., “Mucopolysaccharidosis in a Cat with Arysulfatase B Deficiency: A Model of Maroteaux-Lamy Syndrome,”Science 198:834-836 (1977).
Konde, et al., “Radiographically Visualized Skeletal Changes Associated with Mucopolysaccharidosis Vl in Cats,”Vet Radiol., 28(6):223:228 (1987).
Krivit, et al. “Bone-Marrow Transplantation In The Maroteaux-Lamy Syndrome (Mucopolysaccharidosis Type Vi),”N. Eng. J. Med., 311(25):1606-1611 (1984).
Krivit, “Maroteaux-Lamy Syndrome—Treatment b. Allogeneic Bone Marrow Transplantation in 6 Patients and Potential for Antotransplantation Bone Marrow Gene Insertion,”Intl. Ped. 7:47-52 (1992).
McGovern, et al., “Purification and Properties of Feline and Human Arylsulfatase B Isozymes,”J. Biol. Chem. 257:12605-12610 (1982).
Peters, et al. “Phylogenetic Conservation of Arylsulfatases,”J. Biol. Chem., 265(6)3374-3381 (1990).
Roberts, et al., “Development of a Procedure for Purification of a Recombinant Therapeutic Protein,”Australasien Biotechnol., 6(2):93-99 (1996).
Yogalingam, et al., “Regulation of N-acetylgatactosamine 4-Sulfatase Expression in Retrovirus-Transduced Feline Mucopolysaccharidosis Type VI Muscle Cells,”DNA Cell Biol., 18(3):187-195 (1999).
Chan Wai-Pan
Chen Lin
Fitzpatrick Paul A.
Henstrand John M.
Qin Minmin
Biomarin Pharmaceutical Inc.
Marshall & Gerstein & Borun LLP
Saidha Tekchand
LandOfFree
Precursor N-acetylgalactosamine-4-sulfatase, methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Precursor N-acetylgalactosamine-4-sulfatase, methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Precursor N-acetylgalactosamine-4-sulfatase, methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3445027